591 - Adintrevimab (ADI) Population Pharmacokinetics (PPK) in Phase 1 and Phase 2/3 COVID-19 Prevention and Treatment Study Participants

Thursday, October 20, 2022

12:15 PM – 1:30 PM US ET

Location: Hall B + C

Presenting Author(s)

AC

Anthony P. Cammarata, M.S.

Institute for Clinical Pharmacodynamics
Schenectady, New York, United States
Paul Ambrose, PharmD

Head of Quantitative Pharmacology, Clinical Pharmacology
Adagio Therapeutics
Waltham, New York, United States
PS

Pete Schmidt, MD

VP Clinical Research
Adagio Therapeutics
Waltham, Massachusetts, United States
MP

Myra Popejoy, PharmD

Adagio Therapeutics
Waltham, Massachusetts, United States
JG

Jean Gong, PhD

Adagio Therapeutics
Waltham, Massachusetts, United States
XP

Xia Pu, PhD

clinical pharmacologist
Invivyd, Inc.
Waltham, Massachusetts, United States